Targeting Pediatric Cancer Vulnerabilities

针对儿童癌症的脆弱性

基本信息

  • 批准号:
    10737704
  • 负责人:
  • 金额:
    $ 106.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-19 至 2030-08-31
  • 项目状态:
    未结题

项目摘要

Project Summary / Abstract Despite progress in understanding the molecular basis of childhood malignancies, cancer remains the leading cause of disease-related death in school age children. Moreover, we are still treating these children with old approaches, including cytotoxic chemotherapy, radiation, and surgery, each with associated morbidities. Several roadblocks have hampered progress in treating children with cancer. First, cancer-promoting targets, such as transcription factor fusion oncoproteins, are quite common in pediatrics but make for challenging drug targets. Second, pediatric malignancies tend to have fewer mutations than adult cancers resulting in a decreased likelihood of response to immune checkpoint inhibitors. In sharp contrast, immune checkpoint inhibitors have transformed therapy for subsets of adult cancers. Third, there is a market disincentive for pharmaceutical companies to work on targets that are exclusive to pediatric cancers. Academic investigators must take the lead in de-risking these high priority pediatric targets through comprehensive target validation and identification of initial chemical leads. I am an investigator willing and equipped to take such a risk. I am a physician-scientist, pediatric oncologist innovator and have dedicated my career to the goal of precision pediatric oncology medicine. The time is right to tackle these vexing challenges in childhood cancer therapy development. I will focus predominantly on fusion-driven acute myeloid leukemias (AMLs) and the fusion- driven pediatric solid tumor Ewing sarcoma, two areas of deep expertise in my laboratory. The first objective of my future research program is to target oncogenic fusions in pediatric cancers. We will pioneer new strategies of targeted protein degradation to validate and mechanistically dissect their role in tumor maintenance and to develop inhibitors/degraders that will ultimately inform new therapies. I have led innovative chemical and functional genomic approaches to identify therapeutic targets for childhood cancer, such as the first Pediatric Cancer Dependency Map, genome-scale CRISPR-Cas9 screening in over 100 pediatric cancer models. Novel pediatric specific targets and innovative therapeutic concepts have emerged and will be the focus of our second objective. We aim to deeply understand these targets mechanistically and to identify chemical perturbagens of the top priority dependencies by deploying innovative chemical biology strategies. My third objective leverages my expertise in functional genomics and epigenetics to identify and drug the regulators of key targets of immunotherapies in childhood cancer. My success in these bold endeavors will be ensured by a collaborative team of world-class chemists, structural biologists, immunologists, and epigenetics experts. The discovery of drugs that target pediatric oncogenic fusions and other novel Achilles heels, and the converting of unresponsive childhood malignancies to immunotherapy responsive, would truly be paradigm shifting for children suffering from these diseases.
项目摘要/摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kimberly Stegmaier其他文献

Kimberly Stegmaier的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kimberly Stegmaier', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10688405
  • 财政年份:
    2022
  • 资助金额:
    $ 106.62万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9600133
  • 财政年份:
    2018
  • 资助金额:
    $ 106.62万
  • 项目类别:
Targeting SYK Kinase in AML
在 AML 中靶向 SYK 激酶
  • 批准号:
    10220876
  • 财政年份:
    2017
  • 资助金额:
    $ 106.62万
  • 项目类别:
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
用综合基因组学剖析尤文肉瘤的发病机制
  • 批准号:
    10064577
  • 财政年份:
    2017
  • 资助金额:
    $ 106.62万
  • 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
  • 批准号:
    10457896
  • 财政年份:
    2016
  • 资助金额:
    $ 106.62万
  • 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
  • 批准号:
    10225613
  • 财政年份:
    2016
  • 资助金额:
    $ 106.62万
  • 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
  • 批准号:
    9981667
  • 财政年份:
    2016
  • 资助金额:
    $ 106.62万
  • 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
  • 批准号:
    9328023
  • 财政年份:
    2016
  • 资助金额:
    $ 106.62万
  • 项目类别:
Targeting BET-bromodomains in neuroblastoma
靶向神经母细胞瘤中的 BET-溴结构域
  • 批准号:
    9066220
  • 财政年份:
    2015
  • 资助金额:
    $ 106.62万
  • 项目类别:
Validating Syk as a Target for AML Therapy
验证 Syk 作为 AML 治疗靶点
  • 批准号:
    8296670
  • 财政年份:
    2009
  • 资助金额:
    $ 106.62万
  • 项目类别:

相似海外基金

History of Community and Adult Education in Old Coal Mining Area in Northern Kyushu
九州北部老煤矿区社区与成人教育的历史
  • 批准号:
    26780447
  • 财政年份:
    2014
  • 资助金额:
    $ 106.62万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
High Risk Adult Hepatitis B Vaccination Pilot -Program Area 7
高危成人乙型肝炎疫苗接种试点 - 计划领域 7
  • 批准号:
    8506903
  • 财政年份:
    2012
  • 资助金额:
    $ 106.62万
  • 项目类别:
The San Francisco Bay Area Adult Glioma Survival Study
旧金山湾区成人神经胶质瘤生存研究
  • 批准号:
    7253800
  • 财政年份:
    2007
  • 资助金额:
    $ 106.62万
  • 项目类别:
San Francisco Bay area adult glioma survival study
旧金山湾区成人神经胶质瘤生存研究
  • 批准号:
    6686704
  • 财政年份:
    2002
  • 资助金额:
    $ 106.62万
  • 项目类别:
The San Francisco Bay Area Adult Glioma Survival Study
旧金山湾区成人神经胶质瘤生存研究
  • 批准号:
    8258656
  • 财政年份:
  • 资助金额:
    $ 106.62万
  • 项目类别:
San Francisco Bay area adult glioma survival study
旧金山湾区成人神经胶质瘤生存研究
  • 批准号:
    7550487
  • 财政年份:
  • 资助金额:
    $ 106.62万
  • 项目类别:
The San Francisco Bay Area Adult Glioma Survival Study
旧金山湾区成人神经胶质瘤生存研究
  • 批准号:
    8099448
  • 财政年份:
  • 资助金额:
    $ 106.62万
  • 项目类别:
San Francisco Bay area adult glioma survival study
旧金山湾区成人神经胶质瘤生存研究
  • 批准号:
    7550482
  • 财政年份:
  • 资助金额:
    $ 106.62万
  • 项目类别:
The San Francisco Bay Area Adult Glioma Survival Study
旧金山湾区成人神经胶质瘤生存研究
  • 批准号:
    7885642
  • 财政年份:
  • 资助金额:
    $ 106.62万
  • 项目类别:
San Francisco Bay area adult glioma survival study
旧金山湾区成人神经胶质瘤生存研究
  • 批准号:
    7550492
  • 财政年份:
  • 资助金额:
    $ 106.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了